Contineum Therapeutics

CTNM

Biotechnology · Healthcare

Price

$14.23

+0.22 (+1.57%)

Market Cap

$532.0M

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+10.2% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 25.1M (2021) → 27.7M (2025)

Contineum Therapeutics is a clinical-stage biotechnology company focused on developing drugs for diseases of the central nervous system and inflammation. Its pipeline targets conditions like multiple sclerosis and other neurological or immune-related disorders. The company does not yet sell any approved products and is still running clinical trials to test whether its experimental medicines are safe and effective.

Contineum makes no revenue from product sales today. It funds its operations through cash raised from investors and potentially through research partnerships or licensing deals with larger pharmaceutical companies. Based in the United States, it is a small company with a market cap of roughly $500 million. The main risk it faces is clinical failure — if its drug candidates do not pass trials, the company loses its path to revenue entirely, and it will need to keep raising money to stay operational until it can bring a product to market.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+37.1% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$52M/ year

↑ Rising (+35% vs prior year)

R&D investment increasing — building for the future

Insider Activity

26.2%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~4 months

$20M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

Contineum Therapeutics has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

N/A

—

Data not available

Operating Margin

N/A

—

Data not available

ROCE

-6.6%

Weak — -6.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

Data not available

EPS YoY

N/A

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.03

Conservative — low debt load (0.03)

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial